Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review

被引:59
作者
Hewitt, Catherine [1 ]
Farah, Camile S. [1 ]
机构
[1] Univ Queensland, Sch Dent, Brisbane, Qld 4072, Australia
关键词
bisphosphonate; jaws; osteonecrosis; review; treatment strategies;
D O I
10.1111/j.1600-0714.2007.00540.x
中图分类号
R78 [口腔科学];
学科分类号
1003 [口腔医学];
摘要
Background: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) presents the clinician with significant management dilemmas. The purpose of this study was to distil information related to this disorder by comprehensively reviewing the literature. Methods: The structure and function of bisphosphonates, and their role in the development of BRONJ will be discussed, as will the possible mechanisms through which this pathology develops. A review of cases presented in the literature will be undertaken, and suggestions offered as to the management of this pathology in terms of surgical and conservative approaches. Results: Presentation of BRONJ is currently more common in patients taking intravenous forms of bisphosphonates, but there is a fear that the long-term cumulative effects of oral bisphosphonates may see BRONJ increasingly occurring in this patient group. Conclusions: Prevention is superior to treatment, and the establishment of meticulous oral hygiene and pre-emptive surgical treatment prior to commencement of bisphosphonate therapy is recommended.
引用
收藏
页码:319 / 328
页数:10
相关论文
共 51 条
[1]
Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].
Badros, A ;
Weikel, D ;
Salama, A ;
Goloubeva, O ;
Schneider, A ;
Rapoport, A ;
Fenton, R ;
Gahres, N ;
Sausville, E ;
Ord, R ;
Meiller, T .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952
[2]
Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases [J].
Bagan, JV ;
Murillo, J ;
Jimenez, Y ;
Poveda, R ;
Milian, MA ;
Sanchis, JM ;
Silvestre, FJ ;
Scully, C .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2005, 34 (02) :120-123
[3]
Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal [J].
Bagger, YZ ;
Tankó, LB ;
Alexandersen, P ;
Ravn, P ;
Christiansen, C .
BONE, 2003, 33 (03) :301-307
[4]
Balducci Lodovico, 2003, Cancer Control, V10, P478
[5]
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[6]
Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs [J].
Benford, HL ;
Frith, JC ;
Auriola, S ;
Mönkkönen, J ;
Rogers, MJ .
MOLECULAR PHARMACOLOGY, 1999, 56 (01) :131-140
[7]
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women [J].
Boivin, GY ;
Chavassieux, PM ;
Santora, AC ;
Yates, J ;
Meunier, PJ .
BONE, 2000, 27 (05) :687-694
[8]
Bisphosphonates and avascular necrosis of the jaw: a possible association [J].
Carter, G ;
Goss, AN ;
Doecke, C .
MEDICAL JOURNAL OF AUSTRALIA, 2005, 182 (08) :413-415
[9]
The dental implications of bisphosphonates and bone disease [J].
Cheng, A ;
Mavrokokki, A ;
Carter, G ;
Stein, B ;
Fazzalari, NL ;
Wilson, DF ;
Goss, AN .
AUSTRALIAN DENTAL JOURNAL, 2005, 50 (04) :S4-S13
[10]
Dimitrakopoulos I, 2006, INT J ORAL MAX SURG, V35, P588, DOI 10.1016/j.ijom.2006.02.022